Clinical trial
Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer
NCT00106002 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00106002 |
|---|---|
| Title | Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer |
| Official title | A Phase II Study of Alimta as First Line Chemotherapy for Advanced or Metastatic Breast Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer, Breast Neoplasms, Male, Carcinoma, Ductal |
| Intervention type | Drug |
| Interventions | pemetrexed |
| Enrollment | 37 |
| Start date | Apr 1, 2005 |
| Primary completion | Dec 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Mar 21, 2005 |
| Last update posted | Jun 1, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: